SCHEMBL14009145

SCHEMBL14009145

Cc1ccnc(NC(=O)c2ccc(C(=O)Nc3ccc(-n4cncn4)cc3)s2)c1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 12/20 0.55
▸ RAB9A P51151 12/20 0.55
▸ MEN1 O00255 4/20 0.55
▸ KMT2A Q03164 4/20 0.55
▸ SMN1; SMN2 Q16637 6/20 0.47
▸ PKM P14618 2/20 0.47
▸ HSD17B10 Q99714 1/20 0.44
▸ TP53 P04637 3/20 0.43
▸ GBA1 P04062 1/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ S1PR1 P21453 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ WNT1 P04628 1/20 0.41
▸ DYRK1A Q13627 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14009148 0.86 POLB (0.41) NPC1RAB9AKMT2ASMN1; SMN2GBA1
SCHEMBL14009117 0.84 NPC1 (0.52) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL14009070 0.81 RAB9A (0.51) NPC1RAB9AKMT2AMAPTS1PR1
SCHEMBL14609404 0.81 ROCK1 (0.45) NPC1RAB9AKMT2ASMN1; SMN2MAPT
SCHEMBL14009172 0.80 RAB9A (0.47) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL14009349 0.80 ROCK1 (0.46) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL14009163 0.80 ROCK1 (0.51) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL14009178 0.79 RAB9A (0.47) NPC1RAB9AKMT2ACYP1A2MAPT
SCHEMBL14009217 0.79 RAB9A (0.56) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL14609432 0.79 ROCK1 (0.45) NPC1RAB9AKMT2ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7446195-B2 High affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION (US) 2008-11-04 — — US disclosed
US-7446195-B2 High affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION (US) 2008-11-04 — — US disclosed
US-20070043045-A1 Novel high affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION 2007-02-22 — — US disclosed
US-20070043045-A1 Novel high affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION 2007-02-22 — — US disclosed
WO-2007022258-A1 NOVEL HIGH AFFINITY THIOPHENE-BASED AND FURAN-BASED KINASE LIGANDS SCHERING CORPORATION (US) 2007-02-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043045-A1 Novel high affinity thiophene-based and furan-based kinase ligands CDKL2, CDK2, CDKL1 NPC1 4547/4885RAB9A 3846/4885MEN1 3348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback